Veeva Systems Inc. (NYSE:VEEV) EVP Alan Mateo Sells 3,391 Shares

Veeva Systems Inc. (NYSE:VEEV) EVP Alan Mateo sold 3,391 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $200.86, for a total transaction of $681,116.26. Following the completion of the transaction, the executive vice president now owns 21,983 shares of the company’s stock, valued at $4,415,505.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Veeva Systems Stock Down 0.7 %

VEEV stock opened at $199.10 on Friday. Veeva Systems Inc. has a fifty-two week low of $160.21 and a fifty-two week high of $236.90. The firm’s 50-day simple moving average is $219.63 and its 200 day simple moving average is $202.71. The stock has a market cap of $32.12 billion, a PE ratio of 61.83, a price-to-earnings-growth ratio of 2.03 and a beta of 0.74.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Thursday, February 29th. The technology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. The firm had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. Equities analysts forecast that Veeva Systems Inc. will post 4.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Veeva Systems

A number of institutional investors and hedge funds have recently bought and sold shares of VEEV. OFI Invest Asset Management bought a new position in Veeva Systems in the 3rd quarter valued at about $25,000. Operose Advisors LLC bought a new position in Veeva Systems in the 3rd quarter valued at about $29,000. DSM Capital Partners LLC bought a new position in Veeva Systems in the 4th quarter valued at about $29,000. Vermillion & White Wealth Management Group LLC bought a new position in Veeva Systems in the 4th quarter valued at about $32,000. Finally, Parkside Financial Bank & Trust grew its position in Veeva Systems by 81.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 171 shares of the technology company’s stock valued at $35,000 after buying an additional 77 shares in the last quarter. Institutional investors own 88.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VEEV. Robert W. Baird upped their price target on shares of Veeva Systems from $245.00 to $251.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Citigroup upped their price target on shares of Veeva Systems from $240.00 to $264.00 and gave the company a “buy” rating in a report on Friday, March 1st. StockNews.com raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a report on Friday, April 12th. KeyCorp upped their price target on shares of Veeva Systems from $232.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, March 5th. Finally, Jefferies Financial Group increased their target price on shares of Veeva Systems from $225.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $234.90.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.